Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Decreases By 5.1%

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 5,030,000 shares, a decline of 5.1% from the December 15th total of 5,300,000 shares. Based on an average daily volume of 6,020,000 shares, the short-interest ratio is currently 0.8 days.

Applied DNA Sciences Stock Up 0.7 %

APDN stock opened at $0.19 on Friday. The business’s 50-day moving average price is $0.19 and its 200-day moving average price is $0.55. The stock has a market cap of $10.01 million, a P/E ratio of -0.03 and a beta of 0.40. Applied DNA Sciences has a twelve month low of $0.12 and a twelve month high of $14.40.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings results on Tuesday, December 17th. The technology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. Applied DNA Sciences had a negative net margin of 203.76% and a negative return on equity of 111.18%. On average, equities research analysts expect that Applied DNA Sciences will post -0.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Jane Street Group LLC acquired a new stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned approximately 0.24% of Applied DNA Sciences as of its most recent SEC filing. 22.22% of the stock is currently owned by hedge funds and other institutional investors.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.